GlaxoSmithKline: Bronchitis, Chronic trials

The registry lists 12 Bronchitis, Chronic studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 2 4Phase 3 2No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and Endotypes in ChinaCompletedNCT04853225Results posted
• A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01372410Phase 2Results posted
• 28-day Repeat Dose Study of GSK573719CompletedNCT01030965Phase 2Results posted
• GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary DiseaseCompletedNCT00950807Phase 2Results posted
• Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPDCompletedNCT00749411Phase 2Results posted
• Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of BreathCompletedNCT00442468Results posted
• GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)CompletedNCT00269087Phase 3Results posted
• Etiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) in JapanCompletedNCT03957577
• Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary CareCompletedNCT01516528
• Airflow Limitation in Cardiac Diseases in EuropeCompletedNCT01485159
• Prevalence of Chronic Airway Obstruction in Subjects With a History of Cigarette Smoking in a Primary Care SettingCompletedNCT01013948
• Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)CompletedNCT00269126Phase 3